Thank you for lending your voice and helping take action for those living with pulmonary arterial hypertension (PAH), including systemic scleroderma-associated PAH (SSc-PAH).

The Pulmonary Hypertension Association of Canada (PHA Canada) and Scleroderma Canada (SC) believe that all PAH patients (including those with SSc-PAH) in Canada—no matter their financial situation, province of residence, or private insurance coverage—should have equitable access to optimal treatment. Because PAH is a highly individualized disease, specialized PAH physicians require the flexibility to prescribe any Health Canada-approved treatment they believe will result in the best possible short and long-term outcomes for their patients.

We still need your help to ensure that Canadians affected by PAH (including those with SSc-PAH) have access to any and all treatments available in Canada.

Urgent Issue: Access to Uptravi in British Columbia

Currently, the most urgent issue facing our community is the need to ensure PAH patients (including those with SSc-PAH) have access to Uptravi (selexipag) no matter where they live in Canada.

To date, over 85% of Canadians now have publicly funded access to Uptravi for the treatment of PAH (including SSc-PAH). However, patients living in British Columbia are still waiting for their government to provide the same access to this potentially life-extending treatment option.

In December 2017, the pan-Canadian Pharmaceutical Alliance successfully concluded a pricing agreement for Uptravi. While the PAH and scleroderma communities were excited by this major milestone, advocacy is still needed to ensure that public funding for Uptravi is made available throughout Canada.

To date, Uptravi is accessible through public funding in the following provinces: QuebecNewfoundland and LabradorSaskatchewanManitoba, Alberta, Ontario, and New Brunswick.

Will you take a few minutes to help ensure patients across Canada have equal access to treatment?